Antibacterials/mogamulizumab Reactions 1680, p34 - 2 Dec 2017 Mogamulizumab-induced cutaneous adverse reactions: 6 case reports In a study involving medical review of 25 patients, six patients (3 women and 3 men) aged 44–67 years developed cutaneous adverse reactions during treatment with mogamulizumab. Of these, four patients also received cefepime, cefozopran or piperacillin/tazobactam, which also contributed to the development of mogamulizumab-induced cutaneous adverse reactions (MCARs) [dosages and routes not stated; not all outcomes stated]. All the six patients, who were diagnosed with adult T-cell leukaemia/lymphoma, received treatment with mogamulizumab. After 22–129 days, and after 2-8 cycles of the mogamulizumab therapy, the patients developed grade 2–3 MCARs. Before onsets of MCARs, four out of these six patients started receiving antibacterial therapy with cefepime (2 patients), cefepime and piperacillin/tazobactam (1 patient) and cefozopran (1 patient) for febrile neutropenia. Within two days after the initiation of the antibacterial therapy, the patients developed MCARs. Subsequent immunohistochemical studies of the biopsy specimens revealed multiple CD8+T-cells. The patients were treated with topical/systemic steroids and antihistamines. The mogamulizumab therapy was not discontinued in any of the patient, however, the antibacterial therapy was discontinued in four patients. Within a week after discontinuation of the antibacterial therapy, the skin reaction improved in these four patients. Author comment: "Table 1 summarises the characteristics of 6 patients (25%) who experienced MCARs." "We suspected that drug hypersensitivities were involved in a significant proportion of MCARs." "Given this, the administration of antibiotics was strongly suspected to contribute to MCAR occurrence in 4 patients (cases 2, 3, 4, and 6)." Yasu T, et al. Hypersensitivity reaction to beta-lactam antibiotics in patients with adult t-cell leukemia/lymphoma treated with mogamulizumab. International Journal of Clinical Pharmacology and Therapeutics 55: 807-810, No. 10, Jan 2017. Available from: URL: - Japan 803284042 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial